BBTX — Bambusa Therapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on developing long-acting precision bispecific antibodies designed for care in immunology and inflammation (I&I) and improving patient quality of life. It uses third-party, advanced antibody engineering to create long-acting bispecific antibodies that combine clinically and commercially validated biologic pathways into a single molecule formulated for high-concentration subcutaneous (SubQ) delivery. Its lead product candidate, BBT001, is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated pathways, interleukin-4 receptor alpha and interleukin-31, is designed to simultaneously address core Type 2 inflammation and chronic itch, the two defining burdens of atopic dermatitis (AD) and other inflammatory skin diseases. BBT001 is engineered using validated half-life extension technology with the goal of enabling extended dosing intervals.
Directors
- Howard Liang LED (63)
- Shanshan Xu CHM (43)
- Thang Ho CFD (42)
- Christian Foerster IND (48)
- Crystal Mackay COO (48)
- Jonathan Lieber CFO (57)
- Derek Dirocco IND (46)
- Helmut Jeggle CFD (56)
- Last Annual
- Last Interim
- Incorporated
- March 14th, 2024
- Public Since
- October 30th, 2026
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Address
- 22 Boston Wharf Road, Floor 7, BOSTON, 02210
- Web
- https://bambusatx.com
- Phone
- +1 6178486188
- Auditors
Similar to BBTX
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 24:31 UTC, shares in Bambusa Therapeutics are trading at $15.85. This share price information is delayed by 15 minutes.
Shares in Bambusa Therapeutics last closed at $15.85 and the price had moved by over the past 365 days. In terms of relative price strength the Bambusa Therapeutics share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreBambusa Therapeutics does not currently pay a dividend.
Bambusa Therapeutics does not currently pay a dividend.
Bambusa Therapeutics does not currently pay a dividend.
To buy shares in Bambusa Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $15.85, shares in Bambusa Therapeutics had a market capitalisation of .
Here are the trading details for Bambusa Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BBTX
Based on an overall assessment of its quality, value and momentum Bambusa Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bambusa Therapeutics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $15.85, shares in Bambusa Therapeutics were trading +0.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bambusa Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bambusa Therapeutics' management team is headed by:
- Howard Liang - LED
- Shanshan Xu - CHM
- Thang Ho - CFD
- Christian Foerster - IND
- Crystal Mackay - COO
- Jonathan Lieber - CFO
- Derek Dirocco - IND
- Helmut Jeggle - CFD